Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P30048

UPID:
PRDX3_HUMAN

ALTERNATIVE NAMES:
Antioxidant protein 1; HBC189; Peroxiredoxin III; Peroxiredoxin-3; Protein MER5 homolog; Thioredoxin-dependent peroxiredoxin 3

ALTERNATIVE UPACC:
P30048; B2R7Z0; D3DRC9; E9PH29; P35690; Q0D2H1; Q13776; Q5T5V2; Q96HK4

BACKGROUND:
Antioxidant protein 1, known for its thiol-specific peroxidase activity, catalyzes the reduction of hydrogen peroxide, playing a pivotal role in mitigating oxidative stress within cells. Its synergistic action with MAP3K13 underscores its significance in NF-kappa-B cytosolic activation and the maintenance of cellular integrity.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in diseases such as Spinocerebellar ataxia and Corneal dystrophy, the exploration of Antioxidant protein 1's function offers promising avenues for therapeutic intervention in these genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.